Smithkline Beecham Corporation

Affinium Pharmaceuticals, Inc.

David John Payne

Stewart Campbell Pearson

John Timothy Lonsdale

Daniel Robert Gentry

Nicola Gail Wallis

Joshua M West

John Edward Hodgson

James Raymond Brown

Christopher Michael Traini

Peter Henry Milner

Walter E DeWolf, Jr

Lisa Kathleen Shilling

Alison Frances Chalker

John Hargreaves Bateson

Kenneth H Pearce, Jr

Min Wang

Deborah Dee Jaworski

Mark Andrew Seefeld

Christine Marie Debouck

Alison Francis Chalker

Jeffrey L Mooney

David Richard Witty

Yi Yi Zhong

Desmond John Best

Brian Charles Gasson

Walter E Dewolf, Jr

Marie J Mazzulla

Martin Leonard Gilpin

David G Tew

Glenn Scott Van Aller

Shannon L Reed

John Timothy Londsdale

Lisa Kathleen Schilling

Martin Brandt

Paul M Keller

Arunbhai H Patel

Lisa K Shilling Katz

The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing FabK polypeptides to screen for antibacterial compounds.

FabK variant

The invention provides methods for using agonists and antagonists of FabK polypeptides, particularly to modulate the metabolism of bacteria or to treat bacterial infection.

Methods of agonizing and antagonizing FabK

The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are preferred methods for utilizing FabK polypeptides and polynucleotides as diagnostic reagents and in diagnostic assays to screen for microbial infections in organisms and infestations in materials.

Prokayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I for the treatment of infection, such as bacterial infections. Antagonists against such FAB I and their use as a therapeutic to treat infections, such as staphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FAB I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FAB I and for detecting the polypeptide in a host.

[object Object]

The invention provides methods for identifying agonists and antagonists of FabK polypeptides.

Methods of screening for FabK antagonists and agonists

Prokayrotic FABI polypeptides and DNA (RNA) encoding such FABI and a procedure for such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FABI for the treatment of infection, such as bacterial infections. Antagonists against such FABI and their use as a therapeutic to treat infections, such asstaphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FABI nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FABI and for detecting the polypeptide in a host.

FabI

The invention provides FabH polypeptides and polynucleotides encoding FabH polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing FabH polypeptides to screen for antibacterial compounds.

FabH

Prokayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I for the treatment of infection, such as bacterial infections. Antagonists against such FAB I and their use as a therapeutic to treat infections, such asstaphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FAB I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FAB I and for detecting the polypeptide in a host.

Polynucleotides encoding staphylcoccal FAB I enoyl-ACP reductase

FabD polypeptides and DNA (RNA) encoding such FabD and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FabD for the treatment of infection, particularly bacterial infections. Antagonists against such FabD and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FabD nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding Fab (Fatty acid biosynthesis) and for detecting the polypeptide in a host.

FabD

The invention provides aroA polypeptides and DNA (RNA) encoding aroA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aroA polypeptides to screen for antibacterial compounds.

aroA

The invention provides Div1b polypeptides and DNA (RNA) encoding Div1b polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Div1b polypeptides to screen for antibacterial compounds.

Div1b

.beta.-thiopropionyl-aminoacid derivatives and their use as

The invention provides Divlb polypeptides and DNA (RNA) encoding Divlb polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Divlb polypeptides to screen for antibacterial compounds.

Pyrrolidine and thiazole derivatives with antibacterial and              .

Growing community of inventors

Phoenixville, PA, United States of America

David John Payne